Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Precision Biosciences (DTIL) Interest & Investment Income (2018 - 2025)

Precision Biosciences (DTIL) has disclosed Interest & Investment Income for 8 consecutive years, with $773000.0 as the latest value for Q4 2025.

  • Quarterly Interest & Investment Income fell 48.26% to $773000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.2 million through Dec 2025, down 37.32% year-over-year, with the annual reading at $4.2 million for FY2025, 37.32% down from the prior year.
  • Interest & Investment Income for Q4 2025 was $773000.0 at Precision Biosciences, down from $1.0 million in the prior quarter.
  • The five-year high for Interest & Investment Income was $2.0 million in Q1 2023, with the low at $44000.0 in Q3 2021.
  • Average Interest & Investment Income over 5 years is $1.1 million, with a median of $1.2 million recorded in 2022.
  • The sharpest move saw Interest & Investment Income tumbled 91.97% in 2021, then surged 2974.6% in 2022.
  • Over 5 years, Interest & Investment Income stood at $63000.0 in 2021, then soared by 2974.6% to $1.9 million in 2022, then decreased by 5.68% to $1.8 million in 2023, then fell by 18.23% to $1.5 million in 2024, then crashed by 48.26% to $773000.0 in 2025.
  • According to Business Quant data, Interest & Investment Income over the past three periods came in at $773000.0, $1.0 million, and $1.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.